- Home
- MOLN vs LRMR Comparison
MOLN vs LRMR Comparison
Compare MOLN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- LRMR
- Stock Information
- Founded
- MOLN 2004
- LRMR N/A
- Country
- MOLN Switzerland
- LRMR United States
- Employees
- MOLN N/A
- LRMR N/A
- Industry
- MOLN
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- LRMR Health Care
- Exchange
- MOLN Nasdaq
- LRMR Nasdaq
- Market Cap
- MOLN 183.2M
- LRMR 171.6M
- IPO Year
- MOLN 2021
- LRMR N/A
- Fundamental
- Price
- MOLN $3.89
- LRMR $2.67
- Analyst Decision
- MOLN
- LRMR Strong Buy
- Analyst Count
- MOLN 0
- LRMR 7
- Target Price
- MOLN N/A
- LRMR $18.86
- AVG Volume (30 Days)
- MOLN 2.5K
- LRMR 1.1M
- Earning Date
- MOLN 05-15-2025
- LRMR 08-06-2025
- Dividend Yield
- MOLN N/A
- LRMR N/A
- EPS Growth
- MOLN N/A
- LRMR N/A
- EPS
- MOLN N/A
- LRMR N/A
- Revenue
- MOLN $2,525,030.00
- LRMR N/A
- Revenue This Year
- MOLN N/A
- LRMR N/A
- Revenue Next Year
- MOLN $866.67
- LRMR N/A
- P/E Ratio
- MOLN N/A
- LRMR N/A
- Revenue Growth
- MOLN N/A
- LRMR N/A
- 52 Week Low
- MOLN $3.36
- LRMR $1.61
- 52 Week High
- MOLN $12.70
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- MOLN 49.48
- LRMR 56.20
- Support Level
- MOLN $3.76
- LRMR $2.60
- Resistance Level
- MOLN $4.13
- LRMR $3.02
- Average True Range (ATR)
- MOLN 0.18
- LRMR 0.25
- MACD
- MOLN 0.01
- LRMR 0.01
- Stochastic Oscillator
- MOLN 50.00
- LRMR 51.35
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.